Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case–control study

Rheumatology International

Volumn 36, Issue 6, 2016, Pages 881-889

  Akiyama, Mitsuhiro ^a   Kaneko, Yuko ^a   Yamaoka, Kunihiro ^a   Kondo, Harumi ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Disease activity; Interstitial lung disease; Rheumatoid arthritis; Tocilizumab

Indexed keywords

BIOLOGICAL PRODUCT; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING HABIT; THORAX RADIOGRAPHY; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84963682855     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3478-3     Document Type: Article

References (38)

1. Mori S, Cho I, Koga Y, Sugimoto M (2008) Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 35:1513–1521
2. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627
3. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P et al (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168:159–166
4. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y et al (2007) Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132:214–220
5. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S et al (2009) Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103:846–853
6. Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M et al (2013) Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 3:e003132
7. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66:803–812
8. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP (2002) Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 41:262–267
9. Jani M, Hirani N, Matteson EL, Dixon WG (2014) The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 10:284–294
10. Camille R, Boulos H (2014) Interstitial lung disease induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43:613–626
11. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37
12. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S et al (2011) Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol 38:1585–1592
13. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM et al (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72:43–50
14. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M et al (2015) Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol 25:31–37
15. Kawashiri Y, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K (2012) A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 32:4023–4026
16. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70:2148–2151
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588
19. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824
20. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636–643
21. Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:100–108
22. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
23. Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9:789–793
24. Doyle TJ, Lee JS, Dellaripa PF, Lederer JA, Matteson EL, Fischer A et al (2014) A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 145:454–463
25. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology 53:1676–1682
26. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K (2008) Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 41:1074–1077
27. Mori S, Koga Y, Sugimoto M (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106:1591–1599
28. Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y et al (2014) Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS ONE 9:e92449
29. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46
30. Pérez-Dórame R, Mejía M, Mateos-Toledo H, Rojas-Serrano J (2015) Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Rheumatol Clin 11:12–16
31. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER et al (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106:1040–1047
32. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD (2006) Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 116:3183–3194
33. Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM et al (2005) Increased CD4 + T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 52:73–79
34. Atkins SR, Turesson C, Myers JL, Tazelaar HD, Ryu JH, Matteson EL et al (2006) Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54:635–641
35. Saravanan V, Kelly C (2006) Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 45:787–789
36. Mohr M, Jacobi AM (2011) Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 40:400–401
37. Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ et al (2003) Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 29:490–498
38. Brown KK (2007) Rheumatoid lung disease. Proc Am Thorac Soc 4:443–448